CARDIOMETABOLIC DISEASES
At Avanzia Pharma, we recognize the growing importance of addressing cardiometabolic diseases, which pose a significant challenge to health in the Americas and worldwide. These diseases, which include metabolic disorders and cardiovascular diseases such as hypertension, diabetes, and dyslipidemia, are considered non-communicable diseases (NCDs) and have a significant impact on people’s quality of life.
According to the Pan American Health Organization (PAHO), cardiometabolic diseases have become the leading cause of death in the Americas.
At Avanzia Pharma, we are committed to contributing to the fight against cardiometabolic diseases. We work closely with strategic partners, including innovative pharmaceutical companies and specialized research centers in this field, to develop and market advanced therapeutic solutions.
THE CHALLENGE OF CARDIOMETABOLIC DISEASES
Our approach is established on the continuous search for innovative treatments that help prevent, control, and effectively treat cardiometabolic diseases. We believe in the significance of offering therapeutic options that address both the metabolic and cardiovascular aspects of these disorders, thus providing a comprehensive and personalized approach to patient well-being.
Furthermore, we strive to promote awareness and education about cardiometabolic diseases, both among healthcare professionals and the general population. We recognize the importance of prevention and early detection as fundamental pillars to reduce the burden of these diseases and improve health outcomes.
The pharmaceutical industry understands the importance of a comprehensive approach to managing cardiometabolic diseases. Therefore, strategic alliances have been established with academic institutions, health organizations, and other key stakeholders to foster collaboration and knowledge sharing in the quest for more effective solutions.
THE CRUCIAL ROLE OF THE PHARMACEUTICAL INDUSTRY IN CARDIOMETABOLIC DISEASES
Currently, cardiometabolic diseases represent a significant challenge to global health. These conditions, including metabolic disorders and cardiovascular diseases such as hypertension, diabetes, and dyslipidemia, affect millions of people worldwide and place a considerable burden on both patients and healthcare systems.
The pharmaceutical industry, aware of the magnitude of this problem, has assumed a crucial role in the fight against cardiometabolic diseases. Through the research and development of innovative treatments, as well as the promotion of prevention and awareness of these diseases, pharmaceutical companies are working diligently to improve the cardiovascular and metabolic health of individuals.
SUCCESS STORIES
- Diabetes Mellitus: Promotion of a leading product in more than 12 Latin American countries.
- Digital Hospital with a preventive home-based model, patient-centered, favoring treatment adherence.
- Nurses: Training healthcare professionals on the use of an innovative continuous monitoring system for diabetic patients.
- Promotion of a mature drug indicated for heart failure with annual growth rates of nearly 20%.
- Omnichannel promotion of a family of established antihypertensive products.
BE PART OF OUR TEAM
WORK WITH US
We are an innovative laboratory that adds value to patients through the marketing of high-quality and trusted medications.
If you are passionate about this field and are looking to be part of a team committed to excellence, we invite you to join us.
AVANZIA PHARMA
CONTACT US